Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tissue-Drug Binding: Localization of Drugs and its Significance01:24

Tissue-Drug Binding: Localization of Drugs and its Significance

498
Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine...
498
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

4.2K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
4.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.2K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Tissue Transplantation01:24

Tissue Transplantation

1.1K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial.

Nature communications·2026
Same author

Assessment of colorectal cancer recurrence risk following solid organ transplantation.

Journal of gastrointestinal oncology·2026
Same author

The combination of a cancer vaccine, pembrolizumab, and stereotactic body radiation in patients with locally advanced pancreatic cancer: a single-arm, phase II study.

Nature communications·2026
Same author

Comparative evaluation of SNP sequencing workflows for identification of the missing in Vietnam.

Forensic science international. Genetics·2026
Same author

DNA preservation in highly degraded skeletal remains from the Vietnam war-Characterization and DNA extraction evaluation for nuclear SNP panel testing.

Forensic science international. Genetics·2026
Same author

Postsurgical circulating tumor DNA as a prognostic biomarker for relapse of resected pancreatic ductal adenocarcinoma.

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Mar 1, 2026

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.4K

Tissue-Agnostic Drug Development.

Keith T Flaherty1, Dung T Le1, Steven Lemery1

  • 1From the Massachusetts General Hospital Cancer Center, Boston, MA; The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD; Office of Hematology and Oncology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 1, 2017
PubMed
Summary
This summary is machine-generated.

The U.S. Food and Drug Administration (FDA) traditionally approves drugs for specific tumor types. This paper explores developing drugs agnostic of tumor type, focusing on scientific, clinical, and regulatory aspects.

More Related Videos

Experimental Approaches to Tissue Engineering
16:41

Experimental Approaches to Tissue Engineering

Published on: August 30, 2007

6.8K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.4K

Related Experiment Videos

Last Updated: Mar 1, 2026

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues
08:07

Preclinical Drug Testing in Scalable 3D Engineered Muscle Tissues

Published on: April 7, 2023

4.4K
Experimental Approaches to Tissue Engineering
16:41

Experimental Approaches to Tissue Engineering

Published on: August 30, 2007

6.8K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Regulatory Science

Background:

  • Traditional drug approval focuses on specific tumor sites (e.g., renal cell carcinoma, melanoma).
  • Drug development often targets specific genomic alterations within particular cancer types (e.g., ALK fusions in lung cancer).
  • Heterogeneity in drug response, cancer biology, and natural history necessitates diverse development strategies.

Purpose of the Study:

  • To examine the scientific, clinical trial design, and regulatory considerations for developing tumor-agnostic therapies.
  • To discuss the potential for biomarker-driven drug approvals irrespective of tumor origin.

Main Methods:

  • Review of existing U.S. regulations regarding drug indications and usage.
  • Analysis of scientific and biologic factors influencing drug efficacy across different tumor types.
  • Exploration of clinical trial designs suitable for tissue-agnostic drug development.
  • Discussion of regulatory pathways and challenges for biomarker-based, tumor-agnostic approvals.

Main Results:

  • Current regulations do not mandate disease definition solely by tumor type.
  • Biomarker-driven drug development offers a pathway for tumor-agnostic approvals.
  • Scientific, clinical, and regulatory hurdles exist but can be navigated.

Conclusions:

  • Developing drugs agnostic of tumor type is feasible and supported by regulatory principles.
  • Biomarker-based drug development can broaden treatment options for patients with rare or specific genomic alterations.
  • Further research and adaptive trial designs are crucial for advancing tissue-agnostic therapies.